EXO1 and cancer: We found that double KO EXO1-FANCG and EXO1-ZRSR2 cells are further sensitised by ionising radiation, suggesting that an EXO1-inactivating chemotherapeutic could effectively combine with radiotherapy in the treatment of FA- or ZRSR2-deficient cancers (Fig. 4h, i).